Metanomic Acquires Intoolab, Developers of the First Bayesian Network Artificial Intelligence Engine
Today, Metanomic (https://www.metanomic.net/) announces it has acquired Intoolab A.I (https://www.intoolab.com/) , a Bayesian Network Artificial Intelligence company, to expand and to improve data analysis and A.I across video games and Web3. This acquisition augments Metanomic’s current game economy infrastructure that allows developers to build, simulate and run balanced game economies and core gameplay loops in a live, real-time environment.
The addition of artificial intelligence helps developers create better experiences through intelligent insight from player behaviour in run-time. As a part of the acquisition the existing solution will be rebranded to Thunderstruck and extend the capabilities of the Metanomic Engine.
A more intelligent approach to video game development and Web3 analytics
Thunderstruck is based on a new approach to artificial intelligence that is not based on off the shelf machine learning algorithms but a powerful combination of Deep Learning and Dynamic Bayesian Networks. The solution has already been successfully proven in Healthcare and the technology is now being applied initially to video games and Web3 in a number of core applications -
- Web 3 Intelligence relating to game and NFT discovery and recommendation for tailored and personalized results to the user or player
- Game Economy Intelligence providing Economy Balance Prediction, Gamer Categorisation, Gameplay Recommendations, Retention Strategies and NPC Intelligence
- Ad Categorization delivers analytics around player and consumer classification both on and off-chain for in-game advertising networks to drive more personalized results
- DeFI Intelligence providing on and off-chain user profiling for DeFi insight into asset purchases and income for new products and services, reputation scoring and more.
“Web3 and metaverse are the next big thing that will affect our everyday lives in so many dimensions and we couldn’t be at a better place and time with our technology, to take the next step and introduce Dynamic Bayesian Networks to this untapped and exciting new market,” said Nikos Tzagkarakis, CEO and Co-founder of IntooLab who joins Metanomic as their incoming Chief AI Officer.
“We knew from the first time we met Theo and the rest of the team, that joining the incredible Metanomic powerhouse is our best bet to be part of an unmatched platform for Web3, game economies and the metaverse.
“The incredible traction we’ve seen across both the traditional games industry, web3, and play-and-earn games for the beta of our economy platform already puts us in a strong position to help developers build more fun and engaging experiences,” Theo Priestley, CEO of Metanomic said.
"With the acquisition of an artificial intelligence platform we can deliver more power to developers through real-time player insight as well as the most advanced game economy solution in the industry.”
With the acquisition also comes the commitment to continue to build the company’s development hub in Greece, supporting the local startup community and tech economy.
Thunderstruck is available for trial and partner integration from today. The Metanomic Engine is a complete, free to use game economy design and run-time solution for game developers across Web3 and traditional games and is currently in a closed beta. To sign up for the waiting list email hello@metanomic.net
About Metanomic
Metanomic is the first and only complete real-time economy as a service platform for developers. Built by professional economists and game designers, the platform utilizes patented algorithms to easily deploy plug and play, interoperable and infinitely scalable game and creator economies ready for web3, metaverse, and play-and-earn games. The platform allows developers to easily and quickly build a fully-scalable and configurable play-and-earn economy that features asset creation engines and fully balanced player markets.
About Intoolab
Founded in 2017, Intoolab has always been technology-first, building the first production ready Dynamic Bayesian Networks intelligence that can be a milestone neurosymbolic step towards A.I. frameworks that understand the human concepts structurally and not just correlationally.
Tzager is the first Bayesian Inference A.I. framework, built for biomedical research, drug discovery, and personalized medicine with the main features being Pathway Simulations, Predictor Research/Models, and Literature Intelligence. Tzager is not just another deep learning algorithm trained to solve very specific problems, but an intelligent system with its own framework.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005121/en/
Contact information
Graeme Fraser, Head of Global Marketing
Phone: 07792 758929
Email: graeme@metanomic.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 02:00:00 EET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release
Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release
Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom